Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease(NAFLD) patients with impaired glucose tolerance or type 2 diabetes

Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease(NAFLD) patients with impaired glucose tolerance or type 2 diabetes - TOPIC Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001035

Enrollment

100

Registered

2008-02-15

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Administration of pioglitazone Administration of diabetic medicine except for pioglitazone and metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Non-Alcoholic Fatty Liver Disease accompanied by impaired glucose tolerance or type 2 diabetes

Exclusion criteria

Exclusion criteria: Patients who did not consent to enroll to the study Patients with contraindication for pioglitazone Patients with malignant disease Others who are not suitable to enroll to the study from the physicians points of view

Design outcomes

Primary

Measure	Time frame
NASH activity score	—

Secondary

Measure	Time frame
Fibrosis of liver	—

Countries

Japan

Contacts

Public ContactFutoshi Nagasaki

Sendai City Hospital Gastroenterology

fnagasaki@int3.med.tohoku.ac.jp022-266-7111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026